1Y Target$170.65Near-term target
5Y Target$254.26Compound horizon
10Y Target$661.61Long-dated conviction
FCF—TTM—FCF not applicable for this sector (bank / insurer / REIT) or data unavailable
Rev—TTM YoY—Revenue growth data unavailable · TTM YoY from trailing-4-quarter revenue sum vs prior 4 quarters.
D/E0.00AD/E 0.00 — essentially debt-free, pristine balance sheet
PEG—proxy—PEG not meaningful — earnings growth negative or data unavailable · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Biotechnology · market cap $9.2b. 4% off the 52-week high of $132.00.
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
ROE -52% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon
1-3 yr $170.65 (structural (no analyst coverage)) — catalyst-driven; binary events dominate. 5 yr $254.26 — requires the platform / technology to reach commercial scale. 10 yr $661.61 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.